


Correction to: In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T

Eline A. M. Ruigrok^{1,2} · Giulia Tamborino^{1,3} · Erik de Blois¹ · Stefan J. Roobol^{1,4} · Nicole Verkaik⁴ · Marijke De Saint-Hubert³ · Mark W. Konijnenberg¹ · Wytse M. van Weerden² · Marion de Jong¹ · Julie Nonnekens^{1,4} 

Published online: 26 May 2022

© The Author(s) 2022

Correction to: European Journal of Nuclear Medicine and Molecular Imaging
<https://doi.org/10.1007/s00259-022-05821-w>

The publisher regrets that the Tables 2 and 3 that appear in the original article are incorrect. The correct tables appear below.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Erratum.

The original article can be found online at <https://doi.org/10.1007/s00259-022-05821-w>

✉ Julie Nonnekens
j.nonnekens@erasmusmc.nl

¹ Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands

² Department of Experimental Urology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands

³ Research in Dosimetric Application, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium

⁴ Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands

Table 2 Self-absorbed dose rates to the nucleus per unit activity (Gy(Bq*s)⁻¹) depending on radionuclide localization (i.e. cell membrane and cytoplasm) and cellular dimension (i.e. minimum, average and maximum)

Floating set-up (spherical cells)

Dimension	Source compartment			
	Cell membrane		Cytoplasm	
	Lutetium-177	Actinium-225	Lutetium-177	Actinium-225
Minimum	2.02E-04	1.05E-01	3.67E-04	1.78E-01
Average	1.04E-04	5.63E-02	1.98E-04	1.01E-01
Maximum	6.40E-05	3.56E-02	1.23E-04	6.48E-02

Attached cells set-up (ellipsoidal shape)

Dimension	Source compartment			
	Cell membrane		Cytoplasm	
	Lutetium-177	Actinium-225	Lutetium-177	Actinium-225
Minimum	3.43E-04	1.61E-01	2.14E-04	1.09E-01
Average	1.65E-04	8.31E-02	1.16E-04	6.15E-02
Maximum	7.66E-05	4.05E-02	5.89E-05	3.23E-02

Contribution of the radioactive medium

	Lutetium-177	Actinium-225
	2.30E-11	4.57E-09

Table 3 Absorbed dose (Gy) accumulated over 7 days (i.e. duration of clonogenic survival assay) of either [¹⁷⁷Lu] Lu-PSMA-I&T or [²²⁵Ac] Ac-PSMA-I&T treatment. The absorbed dose is reported for 3 cellular dimension assumptions (i.e. average, minimum and maximum) in order to provide the average and maximum range of variation of the absorbed dose calculations

<i>[¹⁷⁷Lu]Lu-PSMA-I&T</i>				
Concentration (MBq/mL)	Dimension			
	Average	Minimum	Maximum	
0	0	0	0	
0.1	0.74	1.48	0.37	
0.2	1.48	2.96	0.74	
0.3	2.22	4.43	1.11	
0.4	2.96	5.91	1.48	
0.5	3.70	7.39	1.85	

<i>[²²⁵Ac]Ac-PSMA-I&T</i>				
Concentration (kBq/mL)	Dimension			
	Average	Minimum	Maximum	
0	0	0	0	
0.037	0.08	0.16	0.04	
0.1	0.22	0.42	0.11	
0.185	0.41	0.78	0.21	
0.25	0.56	1.05	0.29	
0.37	0.83	1.55	0.42	
0.5	1.12	2.10	0.57	
0.75	1.67	3.15	0.86	